Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer. Vor is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. This technology platform is covered by broad intellectual property exclusively licensed from Columbia University based on the pioneering work of Dr. Siddhartha Mukherjee, as well as Vor’s own intellectual property. Vor is working with some of the world’s leading oncologists and immunologists to develop a pipeline of potentially life-altering immunotherapies that extend beyond what is possible with current treatment. NASDQ: VOR